Notice of Correction in PA-13-315 "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)"

---

Notice Number: NOT-AI-13-063

Key Dates
Release Date: September 3, 2013

Related Announcements
None

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice corrects the language in PA-13-315 entitled "Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)."

Current Language:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Research Objectives and Scope

Research areas appropriate for this FOA include studies of:

• Immunodeficiency resulting from infection (e.g., HIV);
• Immunodeficiency resulting from treatments (e.g., chemotherapy), exposures (e.g., radiation), or therapies (e.g., transplantation, or surgery);
• Immunodeficiency resulting from aging or immaturity; and
• Basic immunologic mechanisms unless related to understanding of primary immunodeficiency disease.

New Language:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Research Objectives and Scope

Research areas NOT supported by this FOA include studies of:

• Immunodeficiency resulting from infection (e.g., HIV);
• Immunodeficiency resulting from treatments (e.g., chemotherapy), exposures (e.g., radiation), or therapies (e.g., transplantation, or surgery);
• Immunodeficiency resulting from aging or immaturity; and
• Basic immunologic mechanisms unless related to understanding of primary immunodeficiency disease.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

David R. Johnson, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3499
Email: drjohnson@niaid.nih.gov

---

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

---